Obesity and Quality of Life in Kidney Transplant Recipients

MC José María[1], R Artacho[2], MJ Aguilar Cordero[1], J Bravo Soto[3], RF Castillo[1]

ABSTRACT

Objective: The objective of this research was to analyse the effects of overweight and obesity in relation to markers of chronic graft dysfunction (ie, dyslipidaemia, high blood pressure and proteinuria), and study their impact on the quality of life of kidney graft recipients in the first year after transplantation.

Methods: This study monitored 1500 kidney transplant recipients of both genders. One year after receiving the graft, all of the patients had blood tests to measure their biochemical parameters. Their weight and height were also measured. Furthermore, data regarding graft loss and delayed renal function were also evaluated.

Results: The results showed an increased prevalence of overweight and high body mass index (BMI) among the graft recipients, participating in the study. Furthermore, there was a direct relation between these parameters and those of health status perception, graft rejection and reduced renal function.

Conclusion: A high BMI, proteinuria, and high blood pressure in the first year after transplantation can lead to chronic graft dysfunction and significantly reduce the patient's quality of life. Renal dysfunction markers along with obesity and a high BMI contributed to a decrease in the glomerular filtration rate (GFR) and ensuing complications in the first year after transplantation. This affected the quality of life of these patients who, as a result, suffered from chronic kidney disease. Consequently, their physical condition was negatively affected, which increased the rates of morbidity and mortality.

Keywords: Kidney transplantation, lipid alterations, obesity anthropometry, quality of life

INTRODUCTION

Within the context of public health and medicine, in general, quality of life is an individual's perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards, and concerns (1). Health professionals often use health-related quality of life to measure the effects of a chronic illness in the patients in order to gain a better understanding of how an illness can affect their daily life (2, 3). Currently, there is a growing interest in studying quality of life in the renal transplant recipients. More specifically, research findings indicate that these patients tend to experience a significant reduction in quality of life in comparison to the general population (4).

The advantages of kidney transplantation are well known. However, life in the post-transplant phase also has negative aspects, such as harsh treatments with immunosuppressive drugs and their related side effects. Furthermore, patients must also endure frequent medical visits, infections, rejection episodes, uncertainty, anxiety and risk of graft loss (5, 6). Therefore, an important task for the future of kidney transplantation is a more detailed specification of the wide range of clinical, environmental and personal factors that can have a negative impact on the patient's health-related quality of life (7). Clearly,

a more in-depth understanding of these factors is crucial in order to develop interventions that can improve the quality of life of renal transplant recipients (8). In line with this, one of the priorities of the World Health Organization (WHO) is also to enhance the quality of life of people who live with those suffering from the chronic illness (9).

Obesity is a factor that significantly worsens the quality of life for patients suffering from the chronic illness. It has an evident impact on their physical condition (10). More specifically, overweight and obesity in the post-transplantation phase can lead to arterial hypertension, proteinuria and dyslipidaemia, all of which can cause kidney damage and delayed renal function. The main objective of this research study was to analyse overweight and obesity in relation to these graft dysfunction factors and evaluate their effect on quality of life in the first year after kidney transplantation.

SUBJECTS AND METHODS

Subjects
The sample population was composed of 1500 kidney transplant recipients, 897 men and 603 women, 16–80 years of age. All of the subjects periodically visited the post-transplant clinic at the University Hospital Virgen de las Nieves in Granada (Spain). The base diseases are shown in Figure 1. All of the patients met the following inclusion criteria: absence of diabetes mellitus before transplantation; stable renal function before transplantation and one-year monitoring period.


Figure 1: Causes of chronic kidney disease

Methods
All of the patients were given blood tests to measure levels of the following: total cholesterol, low-density lipoproteins (LDL), high-density lipoproteins (HDL) and triglycerides. Peripheral blood samples (6 ml) were collected between 8:00 and 9:00 AM by venepuncture into a Venoject II® plastic whole blood tube (TERUMO, autosep®). Blood extraction was performed under fasting conditions. Renal function was measured with the Cockcroft-Gault (CG) formula: GL=((140–age in years) × (weight in kg)) / (72 × serum creatinine)

Renal function deterioration was regarded as an increase in serum creatinine and the presence of high levels of proteinuria. A year after transplantation, the patients were also weighed in kilograms with a Perperson 113481 scale/stadiometer and their height was measured in centimetres. Their body mass index (BMI) was then calculated using the formula: weight (kg)/height (m^2). The subjects' BMI was evaluated based on the following ranges in the WHO classification: (a) underweight (< 18.50); (b) normal weight (18.50–24.9 kg); (c) overweight (25–29.9 kg); (d) obese (> 30 kg). The hypotensive agents used were β-blockers, diuretics, angiotensin-converting enzyme inhibitors (ACE inhibitors) and calcium channel blockers. The immune-suppressive protocol was a triple therapy based on prednisone, consisting of cyclosporine A (CsA) or tacrolimus and microphenolate mofetil (MMF) or azathioprine (AZA).

The dosage of immunosuppressive drugs followed the standard protocol used in the University Hospital Virgen de las Nieves in Granada (Spain). Of the sample, 80% of the graft recipients had taken lipid-lowering agents, such as rosuvastatin, atorvastatin and simvastatin; and they were still being treated with them. Dyslipidaemia was defined as follows: (a) total cholesterol values of > 200 mg/dL (5.17 mmol/L); (b) triglycerides > 200 mg/dL (2.26 mmol/L); (c) diabetes, if fasting blood glucose levels were > 126 mg/dL.

High blood pressure was defined in terms of the criteria established in 2010 by the American Heart Association, namely, blood pressure values exceeding 140/90 mmHg. Proteinuria was regarded as the presence of proteins in the urine, > 150 mg in a 24-hour urine collection. Before being discharged from the hospital, patients were advised to consume 1.4–1.5 g/kg of proteins (30–35 kcal/kg/day) during the first three months after the kidney transplant. Moreover, it was recommended that they avoid sugar and decrease their intake of lipids to less than 30%. After the first three months, patients were advised to reduce their protein intake to 1 g/kg per day. After one year, patients were surveyed and asked about their perception of their health status, specifically in regard to their position as a graft recipient. Accordingly, they had to classify their health status in one of the following categories: (a) Worse than before transplantation; (b) The same as before transplantation; (c) Better than before transplantation.

Statistical analysis

All statistical analyses were performed using the statistical software package SPSS Statistics 20. The results were expressed as frequencies, percentages and mean values ± standard deviation. The differences between groups were evaluated with the analysis of variance (ANOVA). Categories variables were compared with the Chi-square test. All data were expressed as mean value ± standard deviation (X ± SD) and p-values lower than 0.05 were regarded as statistically significant.

RESULTS

As reflected in Table 1, age played a major role in the perception of health status. More specifically, an average of 53.71 patients said that they felt worse than before transplantation, whereas 56.82 patients stated that they felt the same. Differences for parameters, such as gender and height, were not statistically significant.

Our results showed that weight was an important variable. Table 1 shows that the patients' mean weight tended to increase in the pre-transplant phase up to six months to a year after transplantation as patients perceived a deterioration in their health status. In contrast, this was not the case for those who stated that their health had improved after transplantation. In this regard, the parameter of high blood pressure was similar to that of weight. The majority of graft recipients with high blood pressure stated that their health was worse or the same as before transplantation. Only a small percentage said that they felt much better (see Table 1).

Proteinuria was also an important variable. Table 1 shows that as levels of protein increased in urine, patients tended to have a worse perception of their health. As reflected in the value ranges in Table 2, the patients with lower percentages of proteins in their urine said that their health was much better than those with higher percentages (proteinuria). In regard to the highest range of values, the results were very significant in comparison to the other intervals.

When the patients' BMI was categorized with the WHO classification, obese graft recipients with the high BMIs were those that stated that their quality of life was worse than before transplantation. In contrast, there were no differences between over-weight and normal-weight patients whose quality of life was the same as before transplantation. In regard to patients whose quality of life improved after transplantation, there was a higher percentage of overweight patients. Another striking result is the extremely high percentage of overweight and obese patients with renal graft loss within the first year after transplantation (Table 3). Exactly the same occurred in the case of kidney function (Table 4). When the BMI was evaluated based on the WHO classification, our results showed that the percentages of patients with underweight, normal weight, overweight and obesity were all greater in those suffering from delayed graft

Table 1: Comparison of quality of life to anthropometric and biochemical parameters

Variables	Worse than before transplantation	Same as before transplantation	Better than before transplantation	p-value
Age (years)	53.71 ± 12.65	56.82 ± 8.63	45.32 ± 13.81	<0.001
Gender: male/female (%)	76.55/23.5	58.8/41.2	62.5/37.5	NS
Height (cm)	165.79 ± 9.11	164.04 ± 8.20	163.84 ± 9.26	NS
Pre-transplant weight (kg)	70.46 ± 15.07	67.41 ± 12.93	68.33 ± 13,29	NS
Weight (six months afterward) (kg)	74.72 ± 11.61	70.10 ± 13.80	72.48 ± 12.80	NS
Weight (one year afterward) (kg)	76.82 ± 11.24	70.44 ± 13.30	74.42 ± 13.55	NS
Proteinuria (one year) (mg/dL)	0.35	0.31	0.07	0.012
Hypertension (%)	35.7	35.3	21.3	NS
Hyper-lipidaemia (%)	23.5	5.9	23.3	NS

All data expressed as mean+/- Standard deviation, unless otherwise stated
NS: Not significant.

Table 2: Comparison between quality of life and proteinuria levels

Quality of life (one year afterward)	Proteinuria range (one year afterward)				
	< 0.125 g	0.125–0.250 g	0.250–1 g	1–3 g	> 3 g
Worse than before transplantation (%)	66.7		16.7	16.7	
The same as before transplantation (%)	73.3	6.7	6.7	13.3	
Better than before transplantation (%)	89.8	2.9	5.6	1.4	0.3

p < 0.001.

Table 3: Comparison between percentage of patients with graft loss and BMI, according to the WHO (N = 1336)

	BMI according to the WHO classification			
Graft loss within one year	Underweight	Normal weight	Overweight	Obesity
No (%) (N: 1228)	0.4	32.9	39	27.7
Yes (%) (N: 108)			66.7	33.3

NS: Not significant

Table 4: Comparison between delayed renal function (Cockcroft–Gault formula) and BMI, according to the WHO classification

	BMI according to the WHO classification			
Delayed graft function	Underweight	Normal weight	Overweight	Obesity
No (%)	25	49.1	45.8	33.9
Yes (%)	75	50.9	54.2	66.1

$p < 0.01.$

function. The difference had a high level of statistical significance. The patients' quality of life was perceived as poor when renal function was deficient (see Table 5). In contrast, percentages were similar in those patients who stated that their quality of life was better than before transplantation. This difference was also statistically significant.

Table 5: Comparison between quality of life and delayed renal function (Cockcroft–Gault formula)

	Delayed graft function	
Quality of life (one year afterward)	**No**	**Yes**
Worse than before transplantation (%)	13.6	86.4
Same as before transplantation (%)	26.6	73.7
Better than before transplantation (%)	46.1	53.9

$p < 0.01.$

DISCUSSION

The majority of patients in this study were adults, 40–50 years of age (50.8%) with a mean age of 45.0 years (SD = 14.4). This in itself is disturbing because it is a reflection of the early development of kidney disease and its rapid progression in active young people. In this regard, this research differs from previous studies of renal graft recipients, whose age was slightly older (51.1 years) (11).

Evidently, age plays an important role in the acceptance of infirmity. Our results indicate that the kidney transplant patients of a younger age seem to have a greater awareness of the limitations of their illness (12–14). In this regard, various studies show that the kidney graft survival is longer in younger patients (73% and 83%) than in older ones (15–17). According to our results, after the renal transplant, patients experienced a significant gain in weight and BMI (Table 6). This is a serious problem since post-transplant obesity is an important risk factor for the renal graft survival as well as for the development of cardiovascular disease, high blood pressure, diabetes and dyslipidaemias. Furthermore, it is an important cause of morbidity and mortality (18, 19). This is a source of added stress for these graft recipients, who must try to maintain their weight at a level that will not further endanger their health. As reflected in our results, the patients who perceived their health status as the same as before transplantation or worse than before transplantation had the highest BMIs. One reason for this is that they were aware that the weight is a factor that can lead to graft rejection. This is an important problem that must be addressed in clinical work and management because of the possible consequences of overweight and obesity and the difficulty in regaining and maintaining a normal weight (20, 21).

Table 6: Comparison between quality of life and BMI, according to the WHO classification

	BMI according to the WHO classification			
Quality of life (one year afterward)	Underweight	Normal weight	Overweight	Obesity
Worse than before transplantation (%)		18.2	36.4	45.5
Same as before transplantation (%)		41.2	41.2	17.6
Better than before transplantation (%)	0.5	31.1	40.8	27.7

NS: Not significant.

Generally speaking, the kidney transplant patients have suffered from chronic kidney disease over a period of several years. For this reason, many of them experienced lipid disorders even before transplantation (22, 23). Unfortunately, the metabolism of lipids does not return to normal when renal function is recovered after the transplant (24). This signifies that post-transplant renal dyslipidaemia is a relatively frequent metabolic disorder, especially in the first year after transplantation. It is thus of great clinical interest not only because of the high incidence of post-transplant cardiovascular incidents but also because of its possible contribution to the development of chronic graft dysfunction (25). Even though it is not statistically significant, our results point to a possible relation between hyper-lipidaemia and quality of life. Again, the highest percentages pertained to those patients whose quality of life had not improved after transplantation.

Proteinuria was found to be another important factor in our study. When percentages were high, the patients' quality of life significantly worsened because of the ensuing mental, emotional and physical limitations. Physical symptoms include fatigue, lack of energy, sleep disorders, pain, oedemas, general feeling of illness and anxiety. These symptoms reduce the patients' capacity to engage in other activities, especially since there is the need to continuously monitor renal function (26).

Consequently, obesity is frequent in renal graft recipients and is associated with deterioration in cardiovascular parameters and the progression of proteinuria (27–30). As reflected in this study, the patients with a high BMI experienced a reduction in quality of life. Moreover, a high percentage of these patients also suffered from renal graft loss and/or delayed renal function. All of these factors had a negative impact on their health-related quality of life as can be observed in Table 5.

In conclusion, markers of chronic graft dysfunction such as obesity and a high BMI contributed to a reduction in the glomerular filtration rate and ensuing complications in the first year after transplantation. This affected the health-related quality of life of patients with chronic kidney disease by significantly reducing their physical condition and increasing their morbidity and mortality.

REFERENCES
1. Cukor D, Cohen SD, Peterson R, Kimmel PL. Psychosocial aspects of chronic disease: ESRD as a paradigmatic illness. J Am Soc Nephrol 2007; **18:** 3042–55.
2. de Ridder D, Greenen R, Kruijer R, Van Middendorp H. Psychological adjustment to chronic diseases. Lancet 2008; **372:** 246–55
3. Kao TW, Huang JW, Hung KY, Chang YY, Cheng PC, Yen CJ et al. Life expectancy, expected years of life lost and survival of hemodialysis and peritoneal dialysis patients. J Nephrol 2010; **23:** 677–82.
4. Abacı SH, Alagoz S, Salihoglu A. Yalin SF, Gulcicek S, Altiparmak MR. Assessment of anemia and quality of life in patients with renal transplantation. Transplant Proc 2015; **47:** 2875–80.
5. Chmielewski M, Zdrojewski Z, Rutkowski B. Benefits and menaces related to the use of statins in patients after renal transplantation. Ann Transplant 2002; **7:** 6–10.
6. Favaloro R, Peradejordi M, Bertolotti A, Diez M, Favaloro L, Gómez C et al. Results of heart transplantation: 16 years' experience in a center in Argentina. Transplant Proc 2010; **42:** 321–3.
7. Franks P, Hanmer J, Fryback DG. Relative disutilities of 47 risk factors and conditions assessed with seven preference-based health status measures in a national U.S. sample: toward consistency in cost-effectiveness analyses. Med Care 2006; **44:** 478–85.
8. Sharif A, Moore R, Baboolal K. Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia. Transplantation 2008; **85:** 353–8.
9. Ventura CA, Mendes IA, Fumincelli L, Trevizan MA. The evolution of world health organization's initiatives for the strengthening of nursing and midwifery. Nurs Scholarsh 2015; **47:** 435–45.
10. Lew SQ, Piraino B. Quality of life and psychological issues in peritoneal dialysis patients. Semin Dial 2005; **18:** 119–23.
11. Nazemian F, Naghibi M. Weight-gain-related factors in renal transplantation. Exp Clin Transplant 2005; **3:** 329–32.
12. Tonelli M, Moye L, Sacks FM, Kiberd B, Curhan G. Cholesterol and Recurrent Events (CARE) Trial Investigators. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 2003; **138:** 98–104.
13. Seliger SL, Weiss NS, Gillen DL. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 2002; **61:** 297–304.
14. Kisielnicka E, Zdrojewski Z, Wróblewska M, Kortas B, Rutkowski B. Lipid disturbances in a two-year follow-up after successful kidney transplantation. Transplant Proc 2000; **32:** 1358–62.
15. Chmielewski M, Zdrojewski Z, Rutkowski B. Benefits and menaces related to the use of statins in patients after renal transplantation. Ann Transplant 2002; **7:** 6–10.
16. Tse KC, Lam MF, Yip PS, Li FK, Lai KN, Chan TM. A long-term study on hyperlipidemia in stable renal transplant recipients. Clin Transplant 2004; **18:** 274–80.

17. Hernández D, Álvarez A, Torres A. Cardiovascular risk profile in nondiabetic renal transplant patients: cyclosporine versus tacrolimus. Transplant Proc 2003; **35:** 1727–9.

18. Martins L, Ventura A, Costa S, Henriques A, Dias L, Sarmento A. Long-term complications after renal transplantation. Transplant Proc 2003; **35:** 1083–4.

19. Vathsala A, Weinberg RB, Schoenberg L, Grevel J, Goldstein RA, van Buren CT et al. Lipid abnormalities in cyclosporine prednisone treated renal transplant recipients. Transplantation 1989; **48:** 37–43.

20. Kobayashi N, Okubo M, Marumo F, Uchida H, Endo T, Nakamura H. De novo development of hypercholesterolemia and elevated high-density lipoprotein cholesterol: apoprotein A-I ratio in patients with chronic renal failure following kidney transplantation. Nephron 1983; **35:** 237–40.

21. Ettinger WH, Bender WL, Goldberg AP, Hazzard WR. Lipoprotein lipid abnormalities in healthy renal transplant recipients: persistence of low HDL2 cholesterol. Nephron 1987; **47:** 17–21.

22. Booth JC, Joseph JT, Jindal RM. Influence of hypercholesterolemia on patient and graft survival in recipients of kidney transplants. Clin Transplant 2003; **17:** 101–5.

23. Boratynska M, Banasik M, Watorek E, Klinger M, Dorobisz A, Szyber P. Influence of hypercolesterolemia and acute graft rejection on chronic nephropathy development in renal transplant recipient. Transplant Proc 2003; **35:** 2209–12.

24. Beddhu S, Samore MH, Roberts MS, Stoddard GJ, Pappas LM, Cheung AK. Creatinine production, nutrition, and glomerular filtration rate estimation. J Am Soc Nephrol 2003; **14:** 1000–5.

25. Keshaviah PR, Nolph KD, Moore HL, Prowant B, Emerson PF, Meyer M et al. Lean body mass estimation by creatinine kinetics. J Am Soc Nephrol 1994; **4:** 1475–85.

26. Leichtman AB, Cohen D, Keith D, O'Connor K, Goldstein M, McBride V et al. Kidney and pancreas transplantation in the United States, 1997-2006: the HRSA Breakthrough collaboratives and the 58 DSA challenge. Am J Transplant 2008; **8:** 946–57.

27. Ruiz MCL, Castillo RF, de la Rosa RJE, Martínez ARO, Soto JAB. Relación entre función renal y densidad mineral ósea en pacientes trasplantados renales. Revista de Nefrología Diálisis y Trasplante 2012; **1:** 41–5.

28. Molnar MZ, Streja E, Kovesdy CP, Bunnapradist S, Sampaio MS, Jing J et al. Associations of body mass index and weight loss with mortality in transplant-waitlisted maintenance hemodialysis patients. Am J Transplant 2011; **11:** 725–36.

29. Bilbao I, Castells L, Rojas L, Cancino J, Dopazo C, Castro E et al. Immunosuppression based on mycophenolate mofetil in stable liver transplanted patients. Int Immunopharmacol 2006; **20:** 1977–83.

30. Fernández Castillo R, De Alarcon RM, Esteban RJ, Haouari O, Planell E, Perán F et al. Bone mineral density in patients with renal hyperparathyroidism undergoing surgery: relationship with bone parameters. Med Clin (Barc) 2010; **135:** 156–9.